In addition, the study will evaluate cross-reactive immune responses across the sarbecovirus family, including SARS-CoV-2, to assess the vaccine’s potential as a universal coronavirus vaccine. Globally, while multiple companies and research institutions have initiated efforts to develop universal coronavirus vaccines, most programs remain at an early research stage. SK bioscience’s entry into global Phase 1/2 clinical development is the first such vaccine to enter clinical trials, demonstrating a comparatively rapid pace of development. Leveraging strengths on cutting-edge technologies, SK bioscience has been dedicated to promoting human health from prevention to cure across the globe. SK bioscience Communications TeamChanghyun Jin ([email protected])Tae-Gyun Kim ([email protected])Moonchel Kim ([email protected])